Issued 2026-08-13 at $80.59 · now $80.01 (2026-08-13, −0.7% since)
Based on its own history, a month from the 2026-08-13 close, IRON has typically landed between $62.14 and $105.95 — a range of −22.9% to +31.5% from the issuance price $80.59.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,483 overlapping 1 month windows · 2020-08-12 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($80.59) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where IRON has typically landed a month from the 2026-08-13 close of $80.59 — the range is history, not a prediction.
- now $80.01 (-0.7%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $82.65 (+2.6%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $74.31–$90.99
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $62.14–$105.95
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2024-03-04 | −58.7% | −58.7% | +0.0% |
| 2024-03-01 | −57.5% | −57.5% | +0.0% |
| 2024-03-05 | −57.3% | −57.3% | +0.0% |
| 3 best | |||
| 2022-12-27 | +63.6% | +0.0% | +67.3% |
| 2022-12-29 | +63.0% | +0.0% | +67.3% |
| 2023-05-25 | +62.2% | +0.0% | +69.2% |
1,483 overlapping windows · 2020-08-12 – 2026-08-13 · not cherry-picked
Pending catalysts
- September 2026 — Trial primary completion: Phase 3 primary completion: Study of Bitopertin in Participants With EPP or XLP (APOLLO) (source, as of 2026-08-14)
- October 2026 — Trial primary completion: Phase 2 primary completion: Study of DISC-0974-201 in Participants With IBD and Anemia (source, as of 2026-08-14)
- February 2027 — Trial primary completion: Phase 2 primary completion: A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) (source, as of 2026-08-14)
- May 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia (source, as of 2026-08-14)
- June 2028 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.